10th Retroconference - on Retroviruses and Opportunistic Infections

time

Tuesday, February 11

Wednesday, February 12

Thursday, February 13

Friday, February 14

8:30-9 am

2.	Preventing New HIV Infections in the U.S.: What Can We Hope to Achieve Ronald Valdiserri

12.	A Global Perspective on the Clinical Pathology of AIDS Sebastian Lucas

23.	Mechanisms of Action and Resistance to Entry Inhibtors Eric Hunter

9-9:30 am

3.	HIV Vif and the Evasion of Host Antiviral Resistance Michael Malim

13.	Mechanisms of HIV Neuropathogenesis Dana Gabuzda

24.	Pathogenic Mechanisms of HIV Disease: The Multifaceted Effects of VIrus Replication and Viremia on the Host Anthony Fauci

9:30-10 am

break

break (10:30 - 11 am)

10 am- 12:30 pm

4.	New Antiretrovirals
6.	HIV Replication: Entry and Assembly
7.	Immune Responses to HIV
8.	Epidemiology

14.	Immune-Based Therapy
15.	Treatment Strategies
16.	HIV Replication: Integration and Regulation
17.	HIV/SIV Vaccine Studies
18.	Viral Neuropathogenesis
19a.	Maternal-Fetal/Pediatrics/Women's Health
19b.	Microbicides

25.	Viral Pathogenesis
26.	Metabolic and Opportunistic Infectious Complications of HIV Disease
27.	Antiretroviral Drug Resistance
28.	Pharmacologic Consideration in Antiretroviral Therapy
29.	Topics in Primary HIV Infection
30.	HCV, HGV, and Hepatic Complications in HIV-Infected Persons

11 am-1 pm

35b.	Key Therapeutic Decisions in Managing HIV Infection

12:30-1:30 pm

lunch

1:30-3:30 pm

36.	Accessory Genes
37.	RNAi, Lentvirus Vectors, and Gene-Based Therapy
41.	CD4 T-Cell Responses to HIV
42.	CD8 T-Cell Responses to HIV/SIV
48.	Vaccine Adjuvants
49.	Vaccines: Clinical Studies
54.	Viral Reservoirs and Transmission
55.	Viral Reservoirs During Latency and Antiretroviral Therapy
56.	Slow/Non-Progressive Infection
60.	Primary HIV/SIV Infection
66.	New Antiretrovirals
70.	Resistance Testing: Methodology and Clinical Applications
71.	Resistance to HIV-1 Protease Inhibitors
72.	Resistance to HIV-1 Reverse Transcriptase Inhibitors
73.	Resistance to Entry Inhibitors
80.	Diagnostic Tests for HIV
81.	Isolation and Quantification of HIV-1 in Biological Specimens
82.	Microbicides
87.	HIV-Associated Nephropathy
88.	Adverse Drug Reactions Associated with Antiretroviral Drugs
97.	Tuberculosis Treatment in the Setting of Antiretroviral Therapy
98.	HIV-Associated Cytomegalovirus Infection: Immune Correlates and Drug Resistance
99.	Opportunistic Infections: Risks, Incidence, Prevalence, and Outcomes
113.	Molecular Epidemiology
114.	HIV Transmission
115.	Determinants of Disease Progression and Mortality
116.	The HIV/STD Interface
117.	Sex/Gender and HIV-1 Disease Outcomes

38.	Virus Life Cycle: Transcriptional Regulation, Integration, RNA Packaging, and Reverse Transcription
39.	Virus Assembly, Structural Proteins, and Their Co-Factors
43.	Mapping CTL Epitopes in Different Populations
44.	Lymphocyte Dynamics
45.	Immune Response Changes following Antiretroviral Therapy
50.	Neutralizing Antibodies
62.	Genetic Influences on Drug Metabolism
63.	Relationships between Drug Levels and Their Effects
64.	Drug-Drug Interactions
65.	Pharmacology of Novel Antiretroviral Agents
67.	Therapy Experienced Patients
68.	Antiretroviral Therapy: Observational Cohort Studies
77.	Treatment Strategies and Treatment Interruption
78.	Therapeutic Vaccination
79.	Immune Based Therapy: IL-2 and Other Approaches
83.	Neuropathogenesis: Processes in Neuronal Dysfunction
84.	Neuropathogenesis: Surrogate Markers
85.	Neuropathogenesis: Molecular Studies and Models
86.	Neuropathogenesis: Viral Load Analysis
100.	HIV/AIDS-Related Lymphoma
101.	Pathogenesis, Transmission, and Treatment of HHV-8/KSHV Disease
102.	Incidence, Prevalence, and Risks of HIV-Associated Malignancies
103.	HBV: Epidemiology, Natural History and Treatment in Co-Infected Patients
104.	HCV: Epidemiology, Natural History, Pathogenesis, and Impact on HCV Progression
105.	HCV: Therapeutic Progress
106.	GBV-C and SENV: Good, Bad, or Indifferent?
107.	Prevention of Perinatal Transmission (MTCT)
108.	Mechanisms and Determinants of Perinatal Transmission (MTCT)
109.	Disease Progression following Vertical Transmission

40.	Virus Entry, Tropism, and Attachment
46.	DC-SIGN and Related Molecules
47.	Immunology: NK Cell, Cytokine, and Innate Immune Responses
51.	Novel Vaccine Approaches
52.	HIV Vaccines Using Viral Vectors
53.	DNA Vaccines
57.	Viral Pathogenesis: Effects on Host Gene Expression
58.	Viral Replication and Pathogenicity
59.	Viral Genetic Diversity
61.	Treatment Initiated during Primary HIV Infection
69.	Antiretroviral Therapy: Predictors and Correlates of Response
74.	Drug Resistance and Replication Capacity
75.	Drug Resistance in Body and Tissue Compartments
76.	Resistance: Non-Clade B and Epidemiology
89.	Surgical and Cosmetic Treatments for Fat Abnormalities
90.	Interventions for Prevention or Treatment of Lipodystrophy Syndromes
91.	Incidence, Prevalence, and Impact of Body Composition Abnormalities
92.	Cardiovascular Risks and Complications of Antiretroviral Therapy
93.	Dyslipidemia Associated with Antiretroviral Therapy
94.	Pathogenesis and Mechanisms of Lipodystrophy Syndromes
95.	Metabolic and Other Complications in HIV-1-Infected Women
96.	Metabolic and Other Complications in Pediatric HIV Infection
110.	Antiretroviral Clinical Trials in Pediatric HIV-1 Disease
111.	Immunologic Responses during Antiretroviral Therapy in Pediatric HIV-1 Disease
112.	The Effects of Antiretroviral Therapy during Pregnancy

3:30-4 pm

break

4-6 pm

9a.	International Models and Perspectives in Addressing the Pandemic
10.	RNAi: A New Therapeutic Strategy
11.	Impact of Host Genetics on Clinical Outcomes

20	Challenges in Evaluating HIV Vaccine Candidates
21	Virus Interactions with the Host Cell
22	HIV in Women

6-6:30 pm

9b.	Addressing Grand Challenges in AIDS and Global Health Richard Klausner